Tisdag 14 Oktober | 09:34:29 Europe / Stockholm

Prenumeration

Kalender

Est. tid*
2025-11-05 08:00 Kvartalsrapport 2025-Q3
2025-08-22 - Kvartalsrapport 2025-Q2
2025-05-22 - X-dag ordinarie utdelning NEOLA 0.00 SEK
2025-05-21 - Årsstämma
2025-05-21 - Kvartalsrapport 2025-Q1
2025-02-12 - Bokslutskommuniké 2024
2024-11-06 - Kvartalsrapport 2024-Q3
2024-08-15 - Kvartalsrapport 2024-Q2
2024-05-23 - X-dag ordinarie utdelning NEOLA 0.00 SEK
2024-05-22 - Årsstämma
2024-05-22 - Kvartalsrapport 2024-Q1
2024-02-14 - Bokslutskommuniké 2023
2023-12-29 - Extra Bolagsstämma 2023
2023-11-09 - Kvartalsrapport 2023-Q3
2023-08-15 - Kvartalsrapport 2023-Q2
2023-05-19 - X-dag ordinarie utdelning NEOLA 0.00 SEK
2023-05-17 - Årsstämma
2023-05-17 - Kvartalsrapport 2023-Q1
2023-02-14 - Bokslutskommuniké 2022
2022-11-10 - Kvartalsrapport 2022-Q3
2022-09-27 - Extra Bolagsstämma 2022
2022-08-16 - Kvartalsrapport 2022-Q2
2022-05-20 - X-dag ordinarie utdelning NEOLA 0.00 SEK
2022-05-19 - Årsstämma
2022-05-19 - Kvartalsrapport 2022-Q1
2022-02-15 - Bokslutskommuniké 2021
2021-11-09 - Kvartalsrapport 2021-Q3
2021-09-14 - Extra Bolagsstämma 2021
2021-08-17 - Kvartalsrapport 2021-Q2
2021-05-21 - X-dag ordinarie utdelning NEOLA 0.00 SEK
2021-05-20 - Årsstämma
2021-05-20 - Kvartalsrapport 2021-Q1
2021-02-16 - Bokslutskommuniké 2020
2020-11-11 - Kvartalsrapport 2020-Q3

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriMedicinteknik
Neola Medical är verksamt inom medicinteknik. Bolaget är inriktade mot neonatalvården där de utvecklar medicinteknisk utrustning. Exempel på produkter som bolaget tillhandahåller till sjukvården inkluderar teknisk övervakning och uppföljning av lungkapaciteten hos tidigt födda spädbarn. Utöver huvudprodukten erbjuds kringprodukter och engångsartiklar. Störst verksamhet återfinns inom den nordiska marknaden. Bolaget gick tidigare under namnet GPX Medical.
2025-09-25 07:20:00

Neola Medical AB (publ) is pleased to announce the appointment of Eva Bondesson as Clinical Director, effective October 1, 2025. As Neola Medical advances through the clinical phase, Eva Bondesson brings extensive experience that will strengthen the leadership team and support the company’s pathway toward market authorization of Neola®, the company’s medical device for non-invasive, continuous lung monitoring, designed to detect potentially life-threatening lung complications in preterm born babies.

With 30 years of experience in medical technology and in the pharmaceutical industry, combined with a PhD in advanced medical research, with a focus on lung physiology and how the body functions in health and disease, Eva Bondesson brings deep expertise in global clinical development, regulatory processes, and study execution. She has successfully led clinical development strategies to support product approvals and launches across several therapeutic areas, with a particular focus on lung and respiratory diseases.

“We are very pleased to welcome Eva Bondesson to Neola Medical’s leadership team. Her extensive experience in global clinical development, including collaboration with the U.S. FDA and other regulatory authorities, will be highly valuable as we advance through the clinical phase and prepare for our planned U.S. market authorization. With her strong expertise in lung physiology and proven track record in leading international studies, she brings an important complement to our team and to our mission of improving outcomes for preterm born babies,” says CEO Hanna Sjöström. 

“Joining Neola Medical at this exciting stage of its clinical journey is both motivating and meaningful. With extensive experience in clinical studies and regulatory processes, and with a long-standing focus on lung physiology, I look forward to contributing to the company’s next phase and its mission to advance neonatal intensive care,” says Eva Bondesson, incoming Clinical Director at Neola Medical.